基于流感病毒血凝素的通用疫苗研究进展

doi:10.14088/j.cnki.issn0439-8114.2021.14.002

摘要/Abstract

摘要： 流感病毒因其传染性强、流行面广、潜伏期短、发病率高等特点对人类和动物健康构成严重威胁。目前的季节性疫苗只能预防相同亚型的流感病毒的感染,对不同亚型流感病毒不能提供有效的保护,因此能够提供广泛保护性的通用流感疫苗的开发成为流感疫苗研究的重点。简要介绍目前通用流感疫苗的各种制备方法并对基于HA的通用疫苗的研究进展进行综述。

关键词: 甲型流感病毒, 血凝素, 通用疫苗

Abstract: Influenza viruses pose a serious threat to human and animal health due to the strong infectivity, wide spread, short incubation period, and high incidence. The current seasonal vaccine can only prevent the infection of influenza viruses of the same subtype, and are unable to provide effective protection for different subtypes of influenza viruses. Therefore, the development of a universal influenza vaccine that can provide broadly protection has become the focus of current influenza vaccine research. This article will briefly introduce the various preparation methods of the current universal influenza vaccine and review the current research progress of the hemagglutinin-based （HA-based） universal vaccine.

Key words: influenza A virus, hemagglutinin, universal vaccines

中图分类号:

R392.1

孟薇, 张蕾, 黄金海. 基于流感病毒血凝素的通用疫苗研究进展[J]. 湖北农业科学, 2021, 60(14): 10-16.

MENG Wei, ZHANG Lei, HUANG Jin-hai. Progress in research on influenza A virus universal vaccines based on HA[J]. HUBEI AGRICULTURAL SCIENCES, 2021, 60(14): 10-16.

参考文献 86

[1]	LONG J S, MISTRY B, M S. Host and viral determinants of influenza a virus species specificity[J]. Nature reviews microbiology, 2019,17(2):67-81.
[2]	SABBAGHI A, MIRI S M, KESHAVARZ M, et al.Inactivation methods for whole influenza vaccine production[J]. Reviews in medical virology, 2019, 29(6):e2074.
[3]	HUANG K A, RIJAL P, JIANG H, et al.Structure-function analysis of neutralizing antibodies to H7N9 influenza from naturally infected humans[J]. Nature microbiology, 2019, 4(2):306-315.
[4]	BALASUBRAMANI G K, NOWALK M P, SAX T M, et al.Influenza vaccine effectiveness among outpatients in the us influenza vaccine effectiveness network by study site 2011-2016[J]. Influenza and other respiratory viruses, 2020,14(4):380-390.
[5]	张莹. H7N9流感病毒抗HA蛋白单克隆抗体的制备及初步应用[D]. 北京:中国农业科学院, 2019.
[6]	LIU W C, JAN J T, HUANG Y J, et al.Unmasking stem-specific neutralizing epitopes by abolishing N-linked glycosylation sites of influenza virus hemagglutinin proteins for vaccine design[J]. Journal of virology, 2016, 90(19):8496-8508.
[7]	于娟, 李红, 饶华祥, 等. H9N2禽流感病毒血凝素蛋白的主要特性及B/T细胞抗原表位预测分析[J]. 中国病原生物学杂志, 2018, 13(1):11-15.
[8]	AFAGH M, BEHZAD D, NASTARAN K, et al.In silico functional and structural characterization of H1N1 influenza a viruses hemagglutinin, 2010-2013, Shiraz, Iran[J]. Acta biotheoretica, 2015, 63(2):183-202.
[9]	BOWES V A, RITCHIE S J, BYRNE S, et al.Virus characterization, clinical presentation, and pathology associated with H7N3 avian influenza in British Columbia broiler breeder chickens in 2004[J]. Avian diseases, 2004, 48(4):928-934.
[10]	LANGLEY W A, THOENNES S, BRADLEY K C, et al.Single residue deletions along the length of the influenza HA fusion peptide lead to inhibition of membrane fusion function[J]. Virology, 2009, 394(2):321-330.
[11]	DAVID F.Antibody engineering and modification technologies[J]. Biomolecular engineering, 2007, 24(2):201-215.
[12]	LEDESMA J, POZO F, RUIZ M P, et al.Substitutions in position 222 of hemagglutinin of pandemic influenza a (H1N1) 2009 viruses in spain[J]. Journal of clinical virology, 2011, 51(1):75-78.
[13]	SKEHEL J J, WILEY D C.Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin[J]. Annual review of biochemistry, 2000, 69:531-569.
[14]	SHANSHAN G, TIANAO W, ZIYU K, et al.Exploration of binding and inhibition mechanism of a small molecule inhibitor of influenza virus H1N1 hemagglutinin by molecular dynamics simulation[J]. Scientific reports, 2017, 7(1):3786.
[15]	CARR C M, KIM P S.A spring-loaded mechanism for the conformational change of influenza hemagglutinin[J]. Cell, 1993, 73(4):823-832.
[16]	王亚娟, 邢国文. 唾液酸酶和唾液酸糖基转移酶的结构、功能与催化反应研究进展[J]. 有机化学, 2011, 31(8):1157-1168.
[17]	谭刘刚. 山东H9N2亚型禽流感病毒对α-2,6唾液酸受体亲和性变化及血凝素蛋白糖基化对病毒致病性影响的研究[D]. 山东泰安:山东农业大学, 2016.
[18]	殷立伟. H11亚型禽流感病毒囊膜蛋白血凝素的结构与功能研究[D].北京:中国科学院大学, 2017.
[19]	张瑞华,金梅林,王贵华,等. 禽流感血凝素基因的原核表达及其在H9亚型诊断中的应用[J]. 生物工程学报, 2005,21(2):315-319.
[20]	楚电峰. 表达H9亚型禽流感病毒血凝素的重组火鸡疱疹病毒构建及其安全性与免疫效力试验[D]. 江苏扬州:扬州大学, 2018.
[21]	吴玲. A型流感病毒四种亚型同步检测分型方法建立及两株H5N1亚型禽流感病毒地方株的特性研究[D]. 武汉:武汉大学,2013.
[22]	KRAMMER F.Emerging influenza viruses and the prospect of a universal influenza virus vaccine[J]. Biotechnology journal, 2015, 10(5):690-701.
[23]	KATHIE-ANNE W, RUOQING Z, MICHAEL W, et al.Differential effects of influenza virus NA, HA head, and HA stalk antibodies on peripheral blood leukocyte gene expression during human infection[J]. mBio, 2019, 10(3):e00760-e00778.
[24]	KIM K, LEE Y, PARK S, et al.Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus[J]. Virology, 2019, 535:179-188.
[25]	WOHLBOLD T J, NACHBAGAUER R, XU H M, et al.Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice[J]. mBio, 2015, 6(2):e02556-e02569.
[26]	KNIPE D, HOWLEY P, GRIFFIN D E, et al.Fields virology[M]. 6th Ed. Philadelphia:Lippincott Williams & Wilkins, 2013.
[27]	王珏, 刘晔. 流感病毒膜蛋白M2e应用研究进展[J]. 国际免疫学杂志, 2017, 40(1):88-91.
[28]	KIM M, SONG J, EUNJU O, et al.Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus[J]. Molecular therapy, 2013, 21(2):485-492.
[29]	QI M, ZHANG X E, SUN X X, et al.Intranasal nanovaccine confers homo-and hetero-subtypic influenza protection[J]. Small, 2018, 14(13):e1703207.
[30]	MANXIN Z, DARYA Z, KRYSTYNA M, et al.Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza a virus[J]. Molecular immunology, 2006, 43(14):2195-2206.
[31]	LECLERC D,RIVEST M,BABIN C,et al.A novel M2e based flu vaccine formulation for dogs[J]. PLoS One, 2013, 8(10):e77084.
[32]	王丰平. M2e基因诱导的特异性抗流感病毒免疫应答及保护作用[D]. 成都:四川大学,2007.
[33]	MOZDZANOWSKA K, FENG J Q, EID M, et al.Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2[J]. Vaccine, 2003, 21(19):19-20.
[34]	DENIS J, ACOSTA-RAMIREZ E, ZHAO Y, et al.Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform[J]. Vaccine, 2008, 26(27-28):3395-3403.
[35]	FAN W, JING-HE H, XIAO-YI Y, et al.Characterization of immunity induced by M2e of influenza virus[J]. Vaccine, 2007, 25(52):8868-8873.
[36]	DONGMING Z, TE-LANG W, O L M, et al. A universal influenza a vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge[J]. Molecular therapy:The journal of the American society of gene therapy, 2010, 18(12):2182-2189.
[37]	SCHMITZ N, BEERLI R R, BAUER M, et al.Universal vaccine against influenza virus: Linking TLR signaling to anti-viral protection[J]. European journal of immunology, 2012, 42(4):863-869.
[38]	KANG H J, CHU K B, LEE D H, et al.Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs[J]. PLoS One, 2019, 14(6):e216871.
[39]	LEE Y T, KIM K H, KO E J, et al.Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles[J]. Virology, 2019,529:111-121.
[40]	赵敏, 舒刘梅, 高福, 等. H7N9亚型禽流感病毒的T细胞免疫研究[J]. 病毒学报, 2018, 34(6):911-919.
[41]	LEE L Y, HA D L A, SIMMONS C, et al. Memory T cells established by seasonal human influenza a infection cross-react with avian influenza A (H5N1) in healthy individuals[J]. Journal of clinical investigation, 2008, 118(10):3478-3490.
[42]	马晶, 张晓光, 陈红, 等. 含有人H5N1流感病毒Na基因的重组腺病毒候选疫苗株在小鼠体内诱发细胞免疫反应[J]. 病毒学报, 2009, 25(5):327-332.
[43]	ZHAO M,ZHANG H,LIU K,et al.Human t-cell immunity against the emerging and re-emerging viruses[J]. Science china(life sciences), 2017, 60(12):1307-1316.
[44]	张洪波, 姜永萍, 王全英, 等. 禽流感病毒HA基因DNA疫苗诱导鸡CD8~+T细胞的动态变化[J]. 动物医学进展, 2006(11):54-57.
[45]	KRAMMER F, PICA N, HAI R, et al.Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies[J]. Journal of virology, 2013, 87(12):6542-6550.
[46]	LIU J, WU B, ZHANG S H, et al.Conserved epitopes dominate cross-CD8+T-cell responses against influenza A H1N1 virus among Asian populations[J]. European journal of immunology, 2013, 43(8):2055-2069.
[47]	杨明明, WANG Z.肌内免疫后流感病毒特异性功能性CD8~+记忆T细胞群的建立[J]. 微生物学免疫学进展, 2017, 45(6):45.
[48]	牛术孟, 郭志华, 金红. 异型流感病毒感染小鼠T细胞亚群变化研究[J]. 中国病原生物学杂志, 2013, 8(1):23-25.
[49]	WANG Y, DENG L, GONZALEZ G X, et al.Double-layered M2e-NA protein nanoparticle immunization induces broad cross-protection against different influenza viruses in mice[J]. Advanced healthcare materials, 2020, 9(2):1901176.
[50]	BERNSTEIN D I, GUPTILL J, NAFICY A, et al.Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates:Interim results of a randomised, placebo-controlled, phase 1 clinical trial[J]. The lancet infectious diseases, 2020, 20(1):80-91.
[51]	ERIKA A, HUYNH-HOA B, JOHN S, et al.Immunomic analysis of the repertoire of t-cell specificities for influenza a virus in humans[J]. Journal of virology, 2008(24):12241-12251.
[52]	VALKENBURG S A, LI O T, MAK P W, et al.IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection[J]. Proc Natl Acad Sci USA, 2014, 111(15):5676-5681.
[53]	VOGEL O A, MANICASSAMY B.Broadly protective strategies against influenza viruses: Universal vaccines and therapeutics[J]. Frontiers in microbiology, 2020, 11:135.
[54]	RAFFAEL N, PETER P.Development of next generation hemagglutinin-based broadly protective influenza virus vaccines[J]. Current opinion in immunology, 2018, 53:51-57.
[55]	MIRIAM K,RUPERT T,SILKE N,et al.Globular head-displayed conserved influenza H1 hemagglutinin stalk epitopes confer protection against heterologous H1N1 virus[J]. PLoS One,2016,11(4):e0153579.
[56]	SAGAWA H,OHSHIMA A,KATO I,et al . The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region[J].J Gen Virol,1996,77:1483-1487.
[57]	JOHN W T, RAFFAEL N, IRINA M, et al.Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses[J]. Vaccine, 2015, 33(29):3314-3321.
[58]	张立霞, 于在江, 周剑芳, 等. H5N1禽流感病毒Headless HA基因在杆状病毒中的表达[J]. 中华实验和临床病毒学杂志, 2012, 26(3):179-181.
[59]	PARK J K,HAN A,CZAJKOWSKI L,et al.Evaluation of preexisting anti-hemagglutinin stalk antibody as a correlate of protection in a healthy volunteer challenge with influenza A/H1N1pdm virus[J]. ASM journals,2018,9(1):e02284-e02300.
[60]	HAI R, KRAMMER F, TAN G S, et al.Influenza viruses expressing chimeric hemagglutinins:Globular head and stalk domains derived from different subtypes[J]. Journal of virology, 2012, 86(10):5574-5581.
[61]	NATALIE P, RONG H, FLORIAN K, et al.Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses[J]. Proceedings of the national academy of sciences of the United States of America, 2012, 109(7):2573-2578.
[62]	ABDOLI A, SOLEIMANJAHI H, TAVASSOTI KHEIRI M, et al.An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice[J]. Pathogens and disease, 2014, 72(3):197-207.
[63]	MARGINE I,KRAMMER F, HAI R, et al.Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza a viruses[J]. Journal of virology, 2013, 87(19):10435-10436.
[64]	DEMMINGER D E, WALZ L, DIETERT K, et al.Adeno-associated virus-vectored influenza vaccine elicits neutralizing and fcc receptor-activating antibodies[J]. EMBO molecular medicine,2020,12(5):e10938.
[65]	王芙艳. 流感病毒血凝素基因抗流感病毒感染关键序列解析及嵌合基因疫苗的研究[D]. 长沙:中南大学, 2008.
[66]	NACHBAGAUER R, KRAMMER F, ALBRECHT R A.A live-attenuated prime, inactivated boost vaccination strategy with chimeric hemagglutinin-based universal influenza virus vaccines provides protection in ferrets:A confirmatory study[J]. Vaccines, 2018,6:47.
[67]	李佳昕. 表达H5亚型禽流感病毒Mosaic HA蛋白重组火鸡疱疹病毒的构建与免疫效力的测定[D]. 扬州:扬州大学, 2018.
[68]	BAROUCH D H, STEPHENSON K E, BORDUCCHI E N, et al.Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys[J]. Cell, 2013, 155(3):531-539.
[69]	KAMLANGDEE A, KINGSTAD-BAKKE B, ANDERSON T K, et al.Broad protection against avian influenza virus by using a modified vaccinia ankara virus expressing a mosaic hemagglutinin gene[J]. Journal of virology, 2014, 88(22):13300-13309.
[70]	BROECKER F, LIU S T H, SUNTRONWONG N, et al. A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains[J]. NPJ Vaccines, 2019, 4:31.
[71]	KANEKIYO M, JOYCE M G, GILLESPIE R A, et al.Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses[J]. Nature immunology, 2019, 20(3):362-372.
[72]	YAN D, WEI Y, GUO H, et al.The application of virus-like particles as vaccines and biological vehicles[J]. Applied microbiology and biotechnology, 2015, 99(24):10415-10432.
[73]	GALARZA J M, LATHAM T, CUPO A.Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge[J]. Viral immunology, 2005, 18(1):244-251.
[74]	王立强, 许龙, 周晓巍, 等. 应用HA、NA、M1和M2蛋白制备H5N1高致病性禽流感病毒样颗粒[J]. 生物技术通讯, 2011, 22(6):759-763.
[75]	SCHWARTZMAN L M, CATHCART A L, PUJANAUSKI L M, et al.An intranasal virus-like particle vaccine broadly protects mice from multiple subtypes of influenza a virus[J]. mBio, 2015, 6(4):e1044.
[76]	LÓPEZ-MACÍAS C. Virus-like particle (VLP)-based vaccines for pandemic influenza[J]. Human vaccines & immunotherapeutics, 2012,8(3):411-414.
[77]	CREVAR C J, CARTER D M, LEE K Y J, et al. Cocktail of H5N1 cobra HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades[J]. Human vaccines & immunotherapeutics, 2015, 11(3)572-583.
[78]	唐国毅. 基于马赛克HA序列的H9亚型禽流感病毒灭活疫苗初步研究[D]. 武汉:武汉轻工大学, 2019.
[79]	GILES B M, ROSS T M.A computationally optimized broadly reactive antigen (cobra) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets[J]. Vaccine, 2011, 29(16):3043-3054.
[80]	CARTER D M, DARBY C A, JOHNSON S K, et al.Elicitation of protective antibodies against a broad panel of H1N1 viruses in ferrets preimmune to historical H1N1 influenza viruses[J]. Journal of virology, 2017, 91(24): e01283-e01299.
[81]	GILES B M, CREVAR C J, CARTER D M, et al.A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection[J]. The journal of infectious diseases, 2012, 205(10):1562-1570.
[82]	ALLEN J D, OWINO S O, CARTER D M, et al.Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines[J]. Vaccine, 2017, 35(38):5209-5216.
[83]	BOYOGLU-BARNUM S, HUTCHINSON G B, BOYINGTON J C, et al.Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses[J]. Nature communications, 2020, 11(1):791.
[84]	HENRY C, PALM A K, KRAMMER F, et al.From original antigenic sin to the universal influenza virus vaccine[J]. Trends in immunology, 2018, 39(1):70-79.
[85]	许文婷, 罗剑, 郑眉, 等. 甲型H7N9流感病毒疫苗经不同途径免疫小鼠长期保护效果的比较[J]. 中国生物制品学杂志, 2019, 32(5):496-502.
[86]	姚立红, 刘晓宇, 杨琦, 等. 甲型流感病毒分支状M2e多肽疫苗不同途径免疫效果的研究[J]. 中华实验和临床病毒学杂志, 2015, 29(3):199-202.